CTMX CytomX Therapeutics, Inc.
Listings ·
Stockholders voted on June 17, 2026 to raise authorized common stock from 300,000,000 to 600,000,000 shares. The 8-K does not say what the company plans to do with the extra shares.
CytomX priced 45,990,567 shares and pre-funded warrants for 1,179,245 more at $5.300 a share, below the $5.45 last reported sale price on March 17, 2026. Its lead clinical data are interim, and the prospectus gives no patient count or response rate.
Nasdaq closed the matter on May 27, 2025, after the stock closed at $1.00 or above for 10 consecutive trading days. The annual report put the lead programs in Phase 1, and the 8-K gives no cash figures.
Nasdaq said CytomX stock did not hold a $1.00 minimum bid for 30 consecutive business days. The company has 180 calendar days to regain compliance, and the notice has no immediate effect on its listing.
The restructuring focuses the company on CX-2051 and its research collaborations. CytomX expects the changes to extend its cash runway into the second quarter of 2026.
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. Its PROBODY platform creates conditionally activated, masked biologics: the mask reduces binding to the target until proteases in the tumor microenvironment remove it. The platform is being applied to antibody drug conjugates (ADCs), T-cell engagers (TCEs) and cytokines. The company's two current clinical programs, varsetatug masetecan (Varseta-M) and CX-801, are in Phase 1 development. Varseta-M is an investigational, conditionally activated ADC targeting epithelial cell adhesion molecule (EpCAM), initially focused on late-line metastatic colorectal cancer (CRC). Its payload is a topoisomerase-1 inhibitor licensed from AbbVie, formerly ImmunoGen, and the linker is designed to drive bystander killing of neighboring tumor cells. The text notes more than 35,000 patients in the U.S. with third-line or later metastatic CRC. The IND for Varseta-M was allowed to proceed by the FDA in January 2024, and the Phase 1 trial began in April 2024. The company plans to pursue combination strategies to move Varseta-M into earlier lines of therapy starting in 2026, and to potentially initiate development in other EpCAM-expressing tumors in the second half of 2026.
| Product or program | What it is | Stage |
|---|---|---|
| Varseta-M (varsetatug masetecan) | Conditionally activated ADC targeting EpCAM, initially for colorectal cancer | Phase 1 |
| CX-801 | Second current clinical program on the PROBODY platform | Phase 1 |
| PROBODY platform | Masked biologics platform for ADCs, T-cell engagers and cytokines |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $76.2 million | $138.1 million |
| Research and development | $68.7 million | $83.4 million |
| Net income (loss) | -$17.4 million | $31.9 million |
| Cash from operations | -$75.6 million | -$86.2 million |
| Cash and equivalents | $12.7 million | $38.1 million |
| Short-term investments | $124.4 million | $62.6 million |
Our latest story on this, dated Mar 16, 2026: "CytomX files $250,000,000 stock offering, prices it at $5.300 a share". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 26, 2025: "CytomX Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 25, 2025". The story links the filing or release it is based on. Read the story.
CytomX Therapeutics, Inc. trades under the ticker CTMX on NASDAQ.
CytomX Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:6C1; LS:A14158; LSX:A14158.
The SEC Central Index Key (CIK) for CytomX Therapeutics, Inc. is 1501989. Its filings are on SEC EDGAR.
217,899,284 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records CytomX Therapeutics, Inc. under United States.
Our directory classifies CytomX Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for CytomX Therapeutics, Inc. is US23284F1057.
aibio.space lists CytomX Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. Its PROBODY platform creates conditionally activated, masked biologics: the mask reduces binding to the target until proteases in the tumor microenvironment remove it.
Varseta-M (varsetatug masetecan): Conditionally activated ADC targeting EpCAM, initially for colorectal cancer Stage: Phase 1.
CX-801: Second current clinical program on the PROBODY platform Stage: Phase 1.
$76.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio